ATLANTA, GA — May 21, 2002 —
The novel once-daily inhaled COPD treatment tiotropium (Spiriva®) has been shown to improve lung volume, lung function, dyspnea (shortness of breath) and exercise endurance in patients with chronic obstructive pulmonary disease (COPD), according to data presented here today at the annual meeting of the American Thoracic Society.
In a randomized, placebo-controlled study involving 187 COPD patients, those who received tiotropium showed statistically significant improvements in lung volumes and airflow and could exercise for a longer period of time than those who took placebo. In addition to an improved ability to exercise, patients taking tiotropium reported less shortness of breath during exercise and in their daily lives.
“These results confirm the link between improvements in lung volume and the ability to exercise for longer periods of time,” said Dr. Helgo Magnussen, Medical Director of the Centre of Pneumology and Thoracic Surgery in Grosshansdorf, Germany. “This translates into increased ability to participate in daily living -_ something we all strive to achieve for our COPD patients.”
COPD is a slowly progressive airway disease that causes significant deterioration of lung function and consequently, disability and death. Smoking is the leading cause of COPD, but exposure to pollution is another known risk factor. While it is less well known than asthma, COPD is far more prevalent. According to the World Health Organization, about 600 million people suffer from COPD, although many are undiagnosed. Estimates are that by 2020, COPD will be the world’s third leading cause of death.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!